6.90
price up icon1.92%   0.13
after-market Dopo l'orario di chiusura: 6.90
loading
Precedente Chiudi:
$6.77
Aprire:
$6.6
Volume 24 ore:
975.02K
Relative Volume:
15.16
Capitalizzazione di mercato:
$574.58M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-9.21%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$6.60
$7.08
Intervallo di 1 settimana:
Value
$6.60
$7.79
Portata 52W:
Value
$6.60
$7.9999

Niagen Bioscience Inc Stock (NAGE) Company Profile

Name
Nome
Niagen Bioscience Inc
Name
Telefono
310-388-6706
Name
Indirizzo
10900 WILSHIRE BLVD, LOS ANGELES
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
NAGE's Discussions on Twitter

Confronta NAGE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
NAGE
Niagen Bioscience Inc
6.90 574.58M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-08-16 Downgrade Oppenheimer Outperform → Perform
2022-08-11 Downgrade B. Riley Securities Buy → Neutral
2022-03-08 Iniziato ROTH Capital Buy
2019-10-16 Iniziato Oppenheimer Outperform
2019-02-14 Iniziato B. Riley FBR Buy
2017-11-27 Ripresa H.C. Wainwright Buy
2017-09-25 Iniziato Ladenburg Thalmann Buy
2017-01-03 Iniziato Rodman & Renshaw Buy
Mostra tutto

Niagen Bioscience Inc Borsa (NAGE) Ultime notizie

pulisher
08:01 AM

H.C. Wainwright holds $11 target on Niagen Bioscience stock - Investing.com

08:01 AM
pulisher
Mar 29, 2025

A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE) - simplywall.st

Mar 29, 2025
pulisher
Mar 21, 2025

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - MarketScreener

Mar 21, 2025
pulisher
Mar 20, 2025

Niagen Bioscience broadens NAD+ precursor IP portfolio with new patent - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Niagen Bioscience secures new patent for NAD+ precursors - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - Business Wire

Mar 20, 2025
pulisher
Mar 19, 2025

Niagen Bioscience, Inc. Rings the Closing Bell - Nasdaq

Mar 19, 2025
pulisher
Mar 19, 2025

ChromaDex Completes Name Change to Niagen Bioscience -March 19, 2025 at 09:29 am EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Chromadex Rebrands to Niagen Bioscience, Inc. - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science - The Bakersfield Californian

Mar 19, 2025
pulisher
Mar 17, 2025

ChromaDex changes name to Niagen Bioscience to home in on healthy aging - SupplySide Supplement Journal

Mar 17, 2025
pulisher
Mar 17, 2025

Chromadex’s Strategic Rebranding and Promising Clinical Developments Justify Buy Rating - TipRanks

Mar 17, 2025
pulisher
Mar 14, 2025

ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - HBW Insight

Mar 14, 2025
pulisher
Mar 13, 2025

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Bluefield Daily Telegraph

Mar 13, 2025
pulisher
Mar 13, 2025

ChromaDex to rebrand as Niagen Bioscience and change ticker - Investing.com

Mar 13, 2025
pulisher
Mar 11, 2025

Healthy Aging Leader ChromaDex Takes Center Stage at ROTH Conference Longevity Panel - Stock Titan

Mar 11, 2025
pulisher
Mar 06, 2025

ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High - Seeking Alpha

Mar 06, 2025
pulisher
Mar 04, 2025

ChromaDex Reports Strong 2024 Financial Performance - TipRanks

Mar 04, 2025
pulisher
Feb 25, 2025

When Will ChromaDex Reveal Its Q4 Performance? Key Date for NAD+ Leader's Financial Results - Stock Titan

Feb 25, 2025
pulisher
Jan 06, 2025

ChromaDex to Present at Lytham Partners Healthcare Summit, Showcasing NAD+ Research Advances - StockTitan

Jan 06, 2025
pulisher
Jan 02, 2025

Daré Bioscience, Inc. and ARPA-H Ring the Nasdaq Stock Market Closing Bell - Nasdaq

Jan 02, 2025
pulisher
Nov 07, 2024

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide - Business Wire

Nov 07, 2024
pulisher
Sep 11, 2024

Thorne acquires brain health formula partner in $5 million deal - SupplySide Supplement Journal

Sep 11, 2024
pulisher
Sep 11, 2024

The proper role of pre-blends of nutrients in production of dietary supplements - SupplySide Supplement Journal

Sep 11, 2024
pulisher
Sep 10, 2024

FDA Criminal Office Said to Be Examining Drug Ostarine in Dietary Supplements - SupplySide Supplement Journal

Sep 10, 2024
pulisher
Sep 10, 2024

Technology disruption in the dietary supplement industry - SupplySide Supplement Journal

Sep 10, 2024
pulisher
Sep 10, 2024

IV and Injection Offerings to Additional Leading Wellness Clinics - Business Wire

Sep 10, 2024
pulisher
Sep 10, 2024

GMP Requirements for Softgels - SupplySide Supplement Journal

Sep 10, 2024
pulisher
Sep 09, 2024

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions - Business Wire

Sep 09, 2024
pulisher
Jul 23, 2024

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) - Business Wire

Jul 23, 2024
pulisher
May 22, 2024

ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award - Business Wire

May 22, 2024
pulisher
Apr 25, 2024

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - Business Wire

Apr 25, 2024
pulisher
Mar 26, 2024

is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program - Business Wire

Mar 26, 2024
pulisher
Feb 05, 2024

ChromaDex sides with FDA, pharma in NMN supplements debate - SupplySide Supplement Journal

Feb 05, 2024
pulisher
Dec 20, 2023

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen - Business Wire

Dec 20, 2023
pulisher
Dec 12, 2023

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ - PR Newswire

Dec 12, 2023
pulisher
Nov 15, 2023

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients - Business Wire

Nov 15, 2023
pulisher
Nov 03, 2023

ChromaDex and Zesty Paws team up on cellular health for dogs - Longevity.Technology

Nov 03, 2023
pulisher
Nov 01, 2023

(Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD - Business Wire

Nov 01, 2023
pulisher
Oct 26, 2023

ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line - Business Wire

Oct 26, 2023
pulisher
Aug 24, 2023

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NM - Business Wire

Aug 24, 2023
pulisher
Aug 08, 2023

ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness - Business Wire

Aug 08, 2023
pulisher
Jun 20, 2023

Better gummies with Chelamax® magnesium – infographic - SupplySide Supplement Journal

Jun 20, 2023
pulisher
May 10, 2023

Transcript : ChromaDex Corporation, Q1 2023 Earnings Call, May 10, 2023 - Marketscreener.com

May 10, 2023
pulisher
Nov 11, 2022

ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States - Business Wire

Nov 11, 2022
pulisher
Oct 24, 2022

ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards - Business Wire

Oct 24, 2022
pulisher
Oct 12, 2022

How This Global Bioscience Company Got Innovative With Research And Saved Millions - Forbes

Oct 12, 2022
pulisher
Oct 11, 2022

ChromaDex and Nestlé Health Science Announce New Niagen - Business Wire

Oct 11, 2022
pulisher
Sep 01, 2022

ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen - Business Wire

Sep 01, 2022
pulisher
Aug 24, 2022

Longevity supplements report: ChromaDex profile - Longevity.Technology

Aug 24, 2022
pulisher
Aug 23, 2022

Exclusive: ChromaDex’s CEO on Longevity commercialisation - Longevity.Technology

Aug 23, 2022

Niagen Bioscience Inc Azioni (NAGE) Dati Finanziari

Non sono disponibili dati finanziari per Niagen Bioscience Inc (NAGE). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Capitalizzazione:     |  Volume (24 ore):